Quality by Design: Development of the Quality Target Product Profile (QTPP) for Semisolid Topical Products

In recent years, the “quality by design” (QbD) approach has been used for developing pharmaceutical formulations. This is particularly important for complex dosage forms such as topical semisolid products. The first step for developing a product using this efficient approach is defining the quality target product profile (QTPP), a list of quality attributes (QAs) that are required to be present in the final product. These quality attributes are affected by the ingredients used as well as manufacturing procedure parameters. Hence, critical material attributes (CMAs) and critical process parameters (CPPs) need to be specified. Possible failure modes of a topical semisolid product can be determined based on the physiochemical properties of ingredients and manufacturing procedures. In this review, we have defined and specified QTPP, QAs, CMAs and CPPs that are required for developing a topical semisolid product based on the QbD approach.

[1]  Lawrence X. Yu.  Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[2]  G. Anju,et al.  Process Validation of Pharmaceutical Dosages Form: AReview , 2017 .

[3]  S. Jacob,et al.  Basic considerations in the dermatokinetics of topical formulations , 2013 .

[4]  J. G. Rosas,et al.  Quality by design approach of a pharmaceutical gel manufacturing process, part 1: determination of the design space. , 2011, Journal of pharmaceutical sciences.

[5]  Lawrence X. Yu,et al.  Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products , 2012, The AAPS Journal.

[6]  Generic Development of Topical Dermatologic Products, Part II: Quality by Design for Topical Semisolid Products , 2013, The AAPS Journal.

[7]  H. Naé.  Rheological Properties of Topical Formulations , 2016 .

[8]  Emmanuel O. Akala,et al.  Effect of Packaging on Stability of Drugs and Drug Products , 2010 .

[9]  Lan Zhang,et al.  Application of quality by design in the current drug development , 2016, Asian journal of pharmaceutical sciences.

[10]  A. Singer,et al.  Topical drug delivery by a polymeric nanosphere gel: Formulation optimization and in vitro and in vivo skin distribution studies. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Yuuka Shibata,et al.  Comparison of pharmaceutical properties of topical non-steroidal anti-inflammatory drug preparations on quality of life. , 2005, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[12]  K. Nishinari,et al.  Comparison of sugar beet pectin, soybean soluble polysaccharide, and gum arabic as food emulsifiers. 1. Effect of concentration, pH, and salts on the emulsifying properties , 2008 .

[13]  P. W. Carter,et al.  Physicochemical stability of lipid injectable emulsions: correlating changes in large globule distributions with phase separation behavior. , 2007, International journal of pharmaceutics.

[14]  M. Roberts,et al.  Can increasing the viscosity of formulations be used to reduce the human skin penetration of the sunscreen oxybenzone? , 2001, The Journal of investigative dermatology.

[15]  R. A. Nash,et al.  THE VALIDATION OF PHARMACEUTICAL PROCESSES , 1999 .

[16]  V. Sharma,et al.  Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications : A recent review , 2012 .

[17]  Paolo Colombo,et al.  Design of experiments (DoE) in pharmaceutical development , 2017, Drug development and industrial pharmacy.

[18]  Jason R. Stokes,et al.  Measuring the yield behaviour of structured fluids , 2004 .

[19]  Hitesh V. Chavda.  Qbd in Developing Topical Dosage Forms , 2016 .

[20]  J. Hadgraft,et al.  Skin Penetration of Topical Formulations of Ibuprofen 5%: An in vitro Comparative Study , 2003, Skin Pharmacology and Physiology.

[21]  Draft Guidance for Industry. ANDAs: Pharmaceutical Solid Polymorphism. Chemistry, Manufacturing and Controls Information , 2005 .

[22]  J. Bauer.  Polymorphism—A Critical Consideration in Pharmaceutical Development, Manufacturing, and Stability , 2008 .

[23]  J. Hadgraft,et al.  Oxybutynin permeation in skin: the influence of drug and solvent activity. , 2010, International journal of pharmaceutics.

[24]  V. Kett,et al.  High speed DSC (hyper-DSC) as a tool to measure the solubility of a drug within a solid or semi-solid matrix. , 2005, International journal of pharmaceutics.

[25]  H. Maibach,et al.  Bioequivalence of Topical Dermatological Dosage Forms-Methods of Evaluation of Bioequivalence , 1998, Pharmaceutical Research.

[26]  H. Maibach,et al.  Current Challenges in Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products , 2014, Pharmaceutical Research.

[27]  S. H. Fox.  The Theory and Practice of Industrial Pharmacy , 1970 .

[28]  Ajay K Banga,et al.  Quality by design approaches for topical dermatological dosage forms , 2015 .

[29]  L. Buhse,et al.  Topical drug classification. , 2005, International journal of pharmaceutics.

[30]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[31]  Shashank Jain.  QUALITY BY DESIGN (QBD): A COMPREHENSIVE UNDERSTANDING OF IMPLEMENTATION AND CHALLENGES IN PHARMACEUTICALS DEVELOPMENT , 2014 .

[32]  Vivek S. Dave,et al.  Excipient variability and its impact on dosage form functionality. , 2015, Journal of pharmaceutical sciences.

[33]  Michael Kimball.  Manufacturing Topical Formulations: Scale‐up from Lab to Pilot Production , 2016 .

[34]  Cynthia K. Brown,et al.  FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms , 2008, AAPS PharmSciTech.

[35]  L. S. Calixto,et al.  Design and Characterization of Topical Formulations: Correlations Between Instrumental and Sensorial Measurements , 2018, AAPS PharmSciTech.